MedTrace Logo

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

NCT00422799 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2020-10-27

Study results available
· View outcomes & findings →

Summary

In this study, we are trying to find out if the combination of these two drugs is effective in treating Waldenstrom's macroglobulinemia (WM). The combination of these two drugs has not been studied for patients with relapsed or refractory macroglobulinemia. The U.S. Food and Drug Administration (FDA) has approved bortezomib for the treatment of multiple myeloma, a cancer that is closely related to Waldenstrom's macroglobulinemia.

Conditions

  • Waldenstrom's Macroglobulinemia

Interventions

DRUG

Bortezomib

Once weekly for 3 weeks

DRUG

Rituximab

Intravenously once a week for the first and fourth weeks of a cycle

Sponsors & Collaborators

Principal Investigators

  • Irene Ghobrial, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-30
Primary Completion
2015-10-09
Completion
2015-10-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422799 on ClinicalTrials.gov